cholestyramine enteric-coated (ECC) / Pharmascience - LARVOL DELTA

A Study of the Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome (clinicaltrials.gov) - P2a | N=13 | Terminated | Sponsor: Pharmascience Inc. | Trial completion date: Oct 2022 ➔ Dec 2021 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2022 ➔ Dec 2021; Difficult recruitment

Trial completion date • Trial primary completion date • Trial termination • Gastrointestinal Disorder • Short Bowel Syndrome

A Study of the Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome (clinicaltrials.gov) - P2a; N=18; Active, not recruiting; Sponsor: Pharmascience Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Nov 2021 ➔ Oct 2022; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome

A Study of the Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome (clinicaltrials.gov) - P2a; N=18; Recruiting; Sponsor: Pharmascience Inc.; Trial completion date: May 2021 ➔ Nov 2021; Trial primary completion date: Apr 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome

A Study of the Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome (clinicaltrials.gov) - P2a; N=18; Recruiting; Sponsor: Pharmascience Inc.; Trial completion date: Apr 2020 ➔ May 2021; Trial primary completion date: Apr 2020 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome